Human Reproduction, Vol. 15, No. 9, 1898-1902,
September 2000
© 2000 European Society of Human Reproduction and Embryology
A biological, immunological and physico-chemical comparison of the current clinical batches of the recombinant FSH preparations Gonal-F and Puregon
1 Departments of Clinical Biochemistry and 2 Diabetes and Endocrinology, Hope Hospital, Salford, M6 8HD, UK
The immunopotency and in-vitro biopotency of clinical batches of Gonal-F® and Puregon® (recombinant human follicle stimulating hormones) were compared and their carbohydrate chains investigated for charge heterogeneity and internal carbohydrate complexity. Immunopotency (IU/pmol) for both Gonal-F and Puregon was 0.35 ± 0.01 and biopotency (ED50, pmol/l) was similar, being 7.3 ± 0.6 and 5.4 ± 0.2 respectively. Charge distributions were essentially the same with no difference either in median isoelectric point (pI) (between 4.26 and 4.50), or in the bulk of material fractionated between pI 4 and 5 (66.0 ± 1.8% Gonal-F and 72.0 ± 1.8% Puregon). However, there were minor differences in charge at extremes of pI, Gonal-F being slightly more acidic: 18.2% Gonal-F versus 9.8% Puregon at pI 3.5–4.0 (P = 0.03) and 6.7% Gonal-F versus 10.7% Puregon at pI 5.0–5.5 (P = 0.03). Carbohydrate complexity was the same: 9.3 versus 10.9 (complex), 76.6 versus 78.6 (intermediate) and 14.1 versus 10.5% (simple). In summary, Gonal-F and Puregon have similar immunopotency, in-vitro biopotency and internal carbohydrate complexity, differing slightly in charge heterogeneity, Gonal-F having more acidic glycoforms. We conclude them to be intrinsically very similar, expecting no difference in clinical efficacy on the basis of respective structure.
Key words: FSH/glycoforms/Gonal-F/Puregon/rFSH
3 Present address: Nuffield Department of Obstetrics and Gynaecology, John Radcliffe Hospital, Oxford OX3 9DU, UK
4 To whom correspondence should be addressed at: Department of Clinical Biochemistry, Hope Hospital, Salford M6 8HD, UK.E-mail: grahamhorsman{at}mcmail.com
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Balen, P. Platteau, A. N. Andersen, P. Devroey, L. Helmgaard, J.-C. Arce, and for the Bravelle Ovulation Induction (BOI) Study G Highly purified FSH is as efficacious as recombinant FSH for ovulation induction in women with WHO Group II anovulatory infertility: a randomized controlled non-inferiority trial Hum. Reprod., July 1, 2007; 22(7): 1816 - 1823. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gervais, Y.-a. Hammel, S. Pelloux, P. Lepage, G. Baer, N. Carte, O. Sorokine, J.-m. Strub, R. Koerner, E. Leize, et al. Glycosylation of human recombinant gonadotrophins: characterization and batch-to-batch consistency Glycobiology, March 1, 2003; 13(3): 179 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fawzy, R.F. Harrison, P.G. Knight, N. Groome, A. Anderson, W.R. Robertson, and A. Lambert The effect of gonadotrophins with differing LH/FSH ratios on the secretion of the various species of inhibin in women receiving IVF Hum. Reprod., June 1, 2001; 16(6): 1092 - 1097. [Abstract] [Full Text] [PDF]
|
|